Ascendis Pharma A/S (NASDAQ:ASND) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a sell rating in a research report sent to investors on Tuesday.

Other equities analysts also recently issued research reports about the company. Jefferies Financial Group increased their price objective on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Evercore ISI lifted their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. Citigroup lifted their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Wells Fargo & Company boosted their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Finally, The Goldman Sachs Group boosted their price target on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Trading Up 1.8 %

Shares of NASDAQ:ASND opened at $126.51 on Tuesday. The stock’s fifty day simple moving average is $132.30 and its two-hundred day simple moving average is $132.70. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00. The stock has a market cap of $7.67 billion, a PE ratio of -13.59 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds have recently bought and sold shares of the company. Signaturefd LLC increased its holdings in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares in the last quarter. Bessemer Group Inc. grew its position in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares in the last quarter. Pursue Wealth Partners LLC purchased a new position in Ascendis Pharma A/S during the 3rd quarter worth approximately $217,000. Searle & CO. purchased a new position in Ascendis Pharma A/S during the 2nd quarter worth approximately $205,000. Finally, Rhumbline Advisers grew its position in Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.